Zachary Crees

Assistant Clinical Director, Center for Gene and Cellular Immunotherapy (CGCI), Division of Oncology, Section of Hematologic Malignancies · Washington University School of Medicine

Credentials: · · · · ·

History

Center for Gene and Cellular Immunotherapy (CGCI) · Washington University School of Medicine
2022–Present
Washington University School of Medicine
2022–Present

Hematology and Medical Oncology
Washington University/B-JH/SLCH Consortium
2019–2020
2018–2019
Barnes-Jewish Hospital
2015–2018
Internal Medicine
Washington University/B-JH/SLCH Consortium
2015–2016
University of Illinois College of Medicine
2011–2015
University of Colorado College of Liberal Arts and Sciences
2008–2011

Research

NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Journal of the National Comprehensive Cancer Network · 2024 · 118 citations
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial
Nature Medicine · 2023 · First of 32 authors · Corresponding · 62 citations
Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy
Cancer Biology & Therapy · 2014 · 40 citations

John DiPersio
7 papers
Keith Stockerl-Goldstein
7 papers
Mark Schroeder
5 papers
Ravi Vij
5 papers
MS
Michael Slade
4 papers · 2 as a fellow
Geoffrey Uy
3 papers
JG
Jennifer Girard
3 papers · 1 as a fellow
AG
Armin Ghobadi
2 papers
Ceyda Bertram
2 papers
David Spencer
2 papers
Dilan Patel
2 papers · 1 as a fellow
Eric Duncavage
2 papers

Clinical trials

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Principal investigator · Recruiting · Phase 1
Washington University School of Medicine
2026–2028
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization
Principal investigator · Completed · Phase 1
Washington University School of Medicine
2024–2025
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Principal investigator · Completed · Phase 1
Washington University School of Medicine
2023–2025
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Site PI · Recruiting · Phase 1
Umoja Biopharma
2025–2029